# Does Medicaid Cover Ozempic and Wegovy? Same Molecule, Different Answers

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-14 | Updated: 2026-11-10

Canonical page: https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy

> Ozempic and Wegovy are the same molecule under different FDA approvals, and Medicaid's drug benefit follows the approved use, which is why the diabetes label clears and the weight-management label is the one a state may refuse under federal law.

## Key points

- All three uses on the Ozempic label are type 2 diabetes uses. None is weight management, which is why the federal weight-loss exclusion has nothing to bite on.
- Wegovy carries the weight-management approval, plus a cardiovascular indication approved March 8, 2024 on the 17,604-patient SELECT trial and an accelerated approval for noncirrhotic MASH.
- A covered outpatient drug prior authorization decision carries a 24-hour statutory deadline, and a managed-care appeal must be filed within 60 calendar days of the notice.
- Asking a prescriber to record a diagnosis you do not have is a federal crime, and compounded semaglutide is not a covered outpatient drug at all.

[Ozempic and Wegovy](https://glpwatchdog.org/compare/drugs/wegovy-vs-ozempic) contain the same drug. What separates them is what FDA approved each one to do, and Medicaid's drug benefit follows the approved use rather than the ingredient. Ozempic is a type 2 diabetes product and is generally treated as one. Wegovy carries a weight-management approval, and that is the approval a state may refuse to pay for under federal law.[1][2][3]

## Same molecule, two sets of approved uses

Semaglutide reached the market under separate applications, and the two labels list different approved uses.

*Approved indications as printed on the current FDA labels, re-read from DailyMed on October 17, 2026.*

| Product | What the label says it is for |
| --- | --- |
| **Ozempic** (semaglutide injection) | Blood-sugar control in type 2 diabetes, alongside eating and activity changes. Lowering the chance of a heart attack, a stroke or death from cardiovascular causes where type 2 diabetes sits next to established heart disease. Slowing kidney decline, including progression to end-stage kidney disease, where type 2 diabetes sits next to chronic kidney disease.[2] |
| **Wegovy** (semaglutide injection and tablets) | Lowering the same cardiovascular chance in people carrying obesity or overweight who have established heart disease. Reducing body weight and holding that reduction over the long run. And, on the injection only, an accelerated approval covering noncirrhotic MASH where scarring has reached the moderate-to-advanced range.[3] |

Nothing on the Ozempic label is a weight-management indication. All three of its approved uses are diabetes uses. That single fact explains most of what people experience at the pharmacy counter, and it is why the two drugs get different answers from the same program on the same day.

## Why the label decides the coverage answer

Medicaid drug coverage runs on section 1927 of the Social Security Act. Manufacturers who want their drugs paid for sign rebate agreements, and in return states generally cover those drugs. The statute then names a handful of categories a state is allowed to leave out or fence off anyway.[1] Heading that list is medication given, in the statute's own words, to address “anorexia, weight loss, or weight gain.”

The entry does not name semaglutide, or GLP-1 drugs, or any product at all. It attaches to a purpose. A semaglutide prescription written to control blood sugar in diabetes is not medication given to reduce weight, and that entry offers no basis for refusing it. A semaglutide prescription written to bring weight down sits squarely inside it.[1]

CMS describes the resulting landscape in its own words on the page for its 2026 GLP-1 model: Medicare and Medicaid, it says, “generally do not cover these drugs for the weight loss indication.”[4] That sentence concedes the split. Much consumer advice flattens it into “Medicaid does not cover GLP-1s,” which is not what anyone with type 2 diabetes experiences.

## Wegovy's cardiovascular indication, and why an extra indication matters

On March 8, 2024, FDA approved a new use for Wegovy: cutting the chance of cardiovascular death, heart attack and stroke among adults who have heart disease along with obesity or overweight, prescribed alongside eating and activity changes.[5] It was the first weight-loss medication also approved to head off cardiovascular events in that population.

The evidence is the SELECT trial. It randomized 17,604 patients aged 45 or older who already had heart disease, a body-mass index of 27 or greater, and no diabetes history. Over a mean follow-up of 39.8 months, the composite endpoint of death from cardiovascular causes, nonfatal heart attack and nonfatal stroke reached 6.5 percent in the semaglutide arm against 8.0 percent on placebo, a hazard ratio of 0.80 with a 95 percent confidence interval of 0.72 to 0.90. Permanent discontinuation for adverse events ran 16.6 percent versus 8.2 percent, which belongs to the same record and is rarely quoted beside the benefit.[6]

For Medicaid, the new indication matters for legal reasons, not clinical ones. Section 1927 counts a use as medically accepted once FDA has signed off on it under the FD&C Act, and cardiovascular risk reduction in that population now qualifies.[1] A prescription written for that purpose is not, on its face, medication given to reduce weight. The same logic runs through the liver indication, an accelerated approval whose section 1 revision stamp on the label reads August 2025.[3] Tirzepatide arrived at the same position through a sleep apnea approval, which we cover in [the Zepbound version of this question](https://glpwatchdog.org/research/does-medicaid-cover-zepbound).

A second indication does not create an entitlement. Any covered outpatient drug can be put behind prior authorization by the state, no matter what it was prescribed to do.[1] What changes is which rule the argument is about, and that matters when the alternative is a flat refusal to discuss it.

## The line that is not worth crossing

> **Asking a prescriber to record a diagnosis you do not have is fraud, not a strategy.** Federal law makes it a crime to knowingly and willfully make, or cause to be made, a false statement of material fact in an application for payment under a federal health care program, or for use in determining the right to that payment. Medicaid is such a program.[7] It cannot leave you better off, and it puts your prescriber's license at risk along with your benefit.

There is a lawful alternative, and it is simple. If you have not been screened for type 2 diabetes, cardiovascular disease or sleep-disordered breathing, ask whether you should be. If a screening finds something, it was already true. What you are asking for is an assessment, not a code.

## Prior authorization, step therapy, and what each one is

Very little in Medicaid pharmacy is a plain yes or no. Most of it is conditions attached to a yes, and each condition has a name.

- **Preferred drug list.** The set of drugs that dispense with the least friction. A drug that is absent from it is often still payable with paperwork. “Non-preferred” and “not covered” are two different findings, and staff sometimes use them interchangeably.
- **Prior authorization.** Approval required before the pharmacy can dispense. A state may apply it to any covered outpatient drug.[1] A day is the outer limit: the reviewing system owes an answer within 24 hours, over the phone or by comparable means, and the managed-care rules aim plans at that same statutory deadline for drug decisions.[8]
- **Step therapy.** A requirement to try something else first. It is prior authorization with a sequence attached, and the criteria document should say exactly what counts as a trial and how long it must last. Ask for that document rather than for a summary of it.
- **Quantity limits.** Caps on the amount per prescription or the number of refills, which the statute permits within a therapeutic class to discourage waste.[1]

Before you start, note that the 72-hour emergency supply the statute normally guarantees while an authorization is pending carries an explicit exception for the drugs on the excludable list.[1] If your prescription is being processed as a weight-loss agent, that safety net is not there. Our [prior authorization letter tool](https://glpwatchdog.org/tools/glp1-prior-auth-letter-generator) helps assemble the submission, and the criteria your state or plan publishes should drive what goes into it.

## Fee-for-service and managed care are different doors

Which set of documents governs you depends on how your state delivers the benefit. Where the state pays pharmacies itself, its own preferred drug list and criteria are what apply, and a refusal is taken up with the state. Where you are enrolled with [a health plan under contract to the state](https://glpwatchdog.org/research/medicaid-managed-care-and-glp1s), that plan's formulary comes first, and a refusal is taken up with the plan.

A plan cannot simply be stingier than the state that hired it, and Texas plans must adopt the state's Wegovy and Zepbound criteria. The contract rules cap how far it may narrow things: what the plan delivers has to reach at least as far as the fee-for-service benefit does, and its working test for medical necessity cannot be tighter than the one the state applies to itself.[8] Where your state pays for something your plan is refusing, that gap is the argument to make, and it beats repeating the request.

## What to do with a denial

1. **Get the denial in writing and read the reason.** A rejection at the pharmacy carries a code. A plan denial carries an adverse benefit determination notice. The reason given determines everything that follows, and a phone summary of it is not the same document.
2. **File the plan appeal inside 60 calendar days.** That is the federal window, counted from the date on the notice. A managed-care plan may have only one internal level of appeal, and you can file orally or in writing.[9]
3. **Ask for expedited handling if delay would harm you.** Standard resolution runs up to 30 calendar days; expedited runs up to 72 hours. Either can be extended by up to 14 days, and if it is extended without your asking, the plan owes you prompt notice and a written reason within two days.[9]
4. **Go to the state fair hearing if the plan upholds it.** Federal rules name a prior authorization decision as one of the actions carrying a hearing right, and the window to ask for one can run as long as 90 days measured from when the notice went out. Final administrative action is normally due inside 90 days of filing.[10] In fee-for-service, the hearing is where you start rather than where you end up.
5. **Keep the paper.** If the plan misses its own notice or timing deadlines, its appeal counts as exhausted anyway and the hearing opens to you. Proving that takes dates.[9]

## Where federal policy stands in 2026

CMS proposed in November 2024 to reinterpret the statute so anti-obesity medications would be covered under Part D and required in Medicaid. It issued the CY 2026 final rule on April 4, 2025 and announced that it was not finalizing that proposal.[11] The excludable list is unchanged, and no state is required to cover a weight-management prescription.

What exists instead is voluntary. The BALANCE model puts CMS at the table with GLP-1 manufacturers, bargaining over price and coverage terms for whichever state Medicaid agencies and Part D sponsors opt in; the door for a state opened in May 2026 and closes on January 1, 2027. Every formulation of Ozempic, Rybelsus and Wegovy appears on the model's drug list. CMS is careful to say that whether coverage materializes turns on which manufacturers and which states sign up, that the negotiations themselves set who qualifies and can attach prior authorization, and that no individual is guaranteed anything by the model. The Medicare half will not launch in 2027.[4] When we rechecked the model page on October 17, 2026, it gave its stage as Active and its participant count as N/A. No roster of signed-up states has been published.

## A note on compounded semaglutide

People who are denied often ask whether Medicaid will pay for a compounded version instead. It will not, and the reason is definitional rather than discretionary. Section 1927 pays for “covered outpatient drugs,” a term the statute ties to products FDA has approved for safety and effectiveness under the FD&C Act.[1] A compounded preparation is not such a product, so the rebate-and-coverage machinery never reaches it. Compounded supply is a cash market, and what is left of it is on our [compounded semaglutide board](https://glpwatchdog.org/best/compounded-semaglutide).

## State-by-state Medicaid guides

> **We do not keep a 50-state Medicaid coverage table.** Drug lists and criteria documents get revised on timetables of their own, and a table that is accurate today goes on misleading quietly for months after it stops being so. Our [insurance coverage register](https://glpwatchdog.org/insurance) holds what we have been able to check and date, and the [price tracker](https://glpwatchdog.org/price-tracker) shows when each cash figure was last confirmed. Where a coverage claim here looks older than you are comfortable with, the state's own current document is the authority, not us.

Instead, each state guide reads that state’s own drug list and criteria and says when we read them. State guides: [Alabama](https://glpwatchdog.org/research/alabama-medicaid-glp1-coverage), [Alaska](https://glpwatchdog.org/research/alaska-medicaid-glp1-coverage), [Arizona](https://glpwatchdog.org/research/arizona-ahcccs-glp1-coverage), [Arkansas](https://glpwatchdog.org/research/arkansas-medicaid-glp1-coverage), [California](https://glpwatchdog.org/research/does-medi-cal-cover-wegovy-and-zepbound), [Colorado](https://glpwatchdog.org/research/colorado-medicaid-glp1-coverage), [Connecticut](https://glpwatchdog.org/research/connecticut-husky-glp1-coverage), [Delaware](https://glpwatchdog.org/research/delaware-medicaid-glp1-coverage), [District of Columbia](https://glpwatchdog.org/research/dc-medicaid-glp1-coverage), [Florida](https://glpwatchdog.org/research/florida-medicaid-glp1-coverage), [Georgia](https://glpwatchdog.org/research/georgia-medicaid-glp1-coverage), [Hawaii](https://glpwatchdog.org/research/hawaii-medicaid-glp1-coverage), [Idaho](https://glpwatchdog.org/research/idaho-medicaid-glp1-coverage), [Illinois](https://glpwatchdog.org/research/illinois-medicaid-glp1-coverage), [Indiana](https://glpwatchdog.org/research/indiana-medicaid-glp1-coverage), [Iowa](https://glpwatchdog.org/research/iowa-medicaid-glp1-coverage), [Kansas](https://glpwatchdog.org/research/kansas-medicaid-glp1-coverage), [Kentucky](https://glpwatchdog.org/research/kentucky-medicaid-glp1-coverage), [Louisiana](https://glpwatchdog.org/research/louisiana-medicaid-glp1-coverage), [Maine](https://glpwatchdog.org/research/maine-medicaid-glp1-coverage), [Maryland](https://glpwatchdog.org/research/maryland-medicaid-glp1-coverage), [Massachusetts](https://glpwatchdog.org/research/massachusetts-medicaid-glp1-coverage), [Michigan](https://glpwatchdog.org/research/michigan-medicaid-glp1-coverage), [Minnesota and Wisconsin](https://glpwatchdog.org/research/wisconsin-minnesota-medicaid-glp1-coverage), [Mississippi](https://glpwatchdog.org/research/mississippi-medicaid-glp1-coverage), [Missouri](https://glpwatchdog.org/research/missouri-medicaid-glp1-coverage), [Montana](https://glpwatchdog.org/research/montana-medicaid-glp1-coverage), [Nebraska](https://glpwatchdog.org/research/nebraska-medicaid-glp1-coverage), [Nevada](https://glpwatchdog.org/research/nevada-medicaid-glp1-coverage), [New Hampshire](https://glpwatchdog.org/research/new-hampshire-medicaid-glp1-coverage), [New Jersey](https://glpwatchdog.org/research/new-jersey-medicaid-glp1-coverage), [New Mexico](https://glpwatchdog.org/research/new-mexico-medicaid-glp1-coverage), [New York](https://glpwatchdog.org/research/new-york-medicaid-glp1-coverage), [North Carolina](https://glpwatchdog.org/research/north-carolina-medicaid-and-state-health-plan-glp1), [North Dakota](https://glpwatchdog.org/research/north-dakota-medicaid-glp1-coverage), [Ohio](https://glpwatchdog.org/research/ohio-medicaid-glp1-coverage), [Oklahoma](https://glpwatchdog.org/research/oklahoma-medicaid-glp1-coverage), [Oregon](https://glpwatchdog.org/research/oregon-health-plan-glp1-coverage), [Pennsylvania](https://glpwatchdog.org/research/pennsylvania-medicaid-glp1-coverage), [Rhode Island](https://glpwatchdog.org/research/rhode-island-medicaid-glp1-coverage), [South Carolina](https://glpwatchdog.org/research/south-carolina-medicaid-glp1-coverage), [South Dakota](https://glpwatchdog.org/research/south-dakota-medicaid-glp1-coverage), [Tennessee](https://glpwatchdog.org/research/tennessee-tenncare-glp1-coverage), [Texas](https://glpwatchdog.org/research/texas-medicaid-glp1-coverage), [Utah](https://glpwatchdog.org/research/utah-medicaid-glp1-coverage), [Vermont](https://glpwatchdog.org/research/vermont-medicaid-glp1-coverage), [Washington](https://glpwatchdog.org/research/washington-apple-health-glp1-coverage), [West Virginia](https://glpwatchdog.org/research/west-virginia-medicaid-glp1-coverage) and [Wyoming](https://glpwatchdog.org/research/wyoming-medicaid-glp1-coverage). Virginia’s guide is still in progress, and the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker) sets programs side by side.

## Checking your own program

1. **Confirm whether you are fee-for-service or in a managed-care plan.** The number on the back of the card will tell you, and the answer decides which document matters.
2. **Pull the current preferred drug list or plan formulary.** Search it for the brand and for “semaglutide” separately. The two are not always filed together. Our [Medicaid coverage page](https://glpwatchdog.org/insurance/medicaid) tracks which states have added or dropped weight-loss cover.
3. **Request the prior authorization criteria in writing** for the specific product, and ask whether the criteria differ by indication.
4. **Have the pharmacy submit a test claim.** The rejection code tells the prescriber's office precisely what to answer, which a verbal “it's not covered” does not.
5. **Write down the revision date of every document you rely on.** You will need it the next time someone tells you the rule has always been this way.

If none of this works, the cash market is what remains, and questions about your dose, about switching products, or about stopping belong with the prescriber who has been managing you rather than with a coverage page.

If you do end up paying cash, start with sellers that show what they charge before asking for your medical history. [Avono Health](https://glpwatchdog.org/reviews/avono-health) posts every price for its standard and microdose programs, and [Recovery Delivered](https://glpwatchdog.org/reviews/recovery-delivered) lists its prices by dose with a video visit included. [Vitalex Health](https://glpwatchdog.org/reviews/vitalex-health) shows a new-patient starting figure up front, though the final plan price is set after a provider reviews the intake, and [Royal Medical Center](https://glpwatchdog.org/reviews/royal-medical-center) quotes a starting figure without saying which drug, dose or plan it buys.

[Freeley](https://glpwatchdog.org/reviews/freeley) lists its semaglutide price for every plan length before any questions and charges the same at every dose, but its lowest monthly rates depend on a 12- or 24-month plan billed for the full length. [Embody](https://glpwatchdog.org/reviews/embody) also charges one price at every dose, $79 for a one-month supply of compounded semaglutide, and its $49 a month figure is a 12-month plan paid up front at $588.

A few practices straddle insurance and cash, which matters if your coverage changes. [Shapely](https://glpwatchdog.org/reviews/shapely) bills most brand GLP-1s to Medicare and PPO plans, and sells compounded semaglutide to self-pay patients on top of a membership. [Florida Weight Loss MD](https://glpwatchdog.org/reviews/florida-weight-loss-md) prescribes compounded semaglutide or a brand-name GLP-1 where insurance or the case calls for it. [California Trim Clinic](https://glpwatchdog.org/reviews/california-trim-clinic) requires a free discovery call before any order and does not renew automatically, and [NuBloom](https://glpwatchdog.org/reviews/nubloom) shows its compounded semaglutide dose ladder in the open, billed month to month.

## Frequently asked questions

### Does Medicaid cover Ozempic?

Where it is prescribed for its approved diabetes uses, it is generally treated as an ordinary covered outpatient drug, because none of the three indications on its label is weight management. That does not mean no paperwork. States may require prior authorization for any covered drug, and many apply step therapy within the diabetes class. Coverage terms are set state by state.

### Does Medicaid cover Wegovy?

It depends on the state and on what it is prescribed for. Under federal law, a state may exclude agents used for weight loss, and many states have. Wegovy also carries a cardiovascular risk reduction indication and, under accelerated approval, a MASH indication, and neither of those is a weight-loss use. Whether a given program recognizes that distinction is a question for that program's criteria document.

### Is semaglutide covered by Medicaid?

The question needs a product and a purpose attached before it can be answered. Semaglutide reaches the market as Ozempic (the pen, and the tablets that are replacing Rybelsus) on diabetes approvals, and as Wegovy on weight-management and cardiovascular ones, and Medicaid's drug rules turn on the approved use. Compounded semaglutide is not covered at all, because it is not an FDA-approved product and so is not a covered outpatient drug under the statute.

### Can my doctor write it for diabetes so it will be covered?

Not unless you have diabetes. Knowingly making a false statement of material fact to obtain payment from a federal health care program is a crime, and Medicaid is one. If you have never been screened, ask to be. A real result changes the picture legitimately; a recorded one you do not have puts your prescriber and your benefit at risk.

### Why did my pharmacy fill it last year and refuse this year?

The lists and rules sitting behind a fill get rewritten on a schedule you never see, and health plans reset their formularies at the contract year. A fill that went through in the past proves what the rule was in the past. Ask for the current criteria document and its revision date rather than arguing from an old receipt.

## References

1. United States Code 42 U.S.C. §1396r-8 — Payment for covered outpatient drugs (Social Security Act §1927), subsections (d)(1), (d)(2), (d)(5), (d)(6), (k)(2) and (k)(6). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8
2. Novo Nordisk Pharmaceutical Industries, LP OZEMPIC (semaglutide) injection, solution — prescribing information, §1 Indications and Usage. DailyMed SPL SetID adec4fd2-6858-4c99-91d4-531f5f2a2d79. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
3. Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection, solution and WEGOVY (semaglutide) tablet — prescribing information, §1 Indications and Usage. DailyMed SPL SetID ee06186f-2aa3-4990-a760-757579d8f77b. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
4. CMS Innovation Center BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model. Centers for Medicare & Medicaid Services. 2026. https://www.cms.gov/priorities/innovation/innovation-models/balance
5. U.S. Food and Drug Administration FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. FDA News Release, March 8, 2024. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/
7. United States Code 42 U.S.C. §1320a-7b(a) — Criminal penalties for acts involving Federal health care programs: making or causing to be made false statements or representations. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1320a-7b
8. Code of Federal Regulations 42 CFR §438.210 — Coverage and authorization of services. Electronic Code of Federal Regulations. 2026. https://www.ecfr.gov/current/title-42/section-438.210
9. Code of Federal Regulations 42 CFR part 438 subpart F — Grievance and Appeal System (§§438.402, 438.408, 438.420). Electronic Code of Federal Regulations. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-438/subpart-F
10. Code of Federal Regulations 42 CFR part 431 subpart E — Fair Hearings for Applicants and Beneficiaries (§§431.220, 431.221, 431.244). Electronic Code of Federal Regulations. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-431/subpart-E
11. Centers for Medicare & Medicaid Services Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-F). CMS Fact Sheet, April 4, 2025. 2025. https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription-final

---

Cite as: GLP Watchdog, Nora Bissett, "Does Medicaid Cover Ozempic and Wegovy? Same Molecule, Different Answers", published 2026-08-14, updated 2026-11-10. https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy

Canonical HTML page: https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.